No annual revenue total was found in ADIAL PHARMACEUTICALS, INC.'s SEC filings.
Adial Pharmaceuticals, Inc. (AZR) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-57.80M
-584.0% vs year-ago TTM
Operating cash flow (TTM)
$-11.13M
-71.7% vs year-ago TTM
Free cash flow
$-12.01M
EPS (TTM)
$-29.12
-585.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
1.43M
-78.3% vs prior year
Net cash
$3.79M
FY 2022
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AZR (Nasdaq), ADIL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Encino, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1513525
- Former names
- ADIAL PHARMACEUTICALS, INC. (until Oct 30, 2026); Adial Pharmaceuticals, L.L.C. (until Sep 28, 2017); ADial Pharmaceuticals, L.L.C. (until Sep 28, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$7.8M | -$8.3M | -$6.9M | -$10.9M | -$19.3M |
| Net income | -$8.0M | -$13.2M | -$5.1M | -$12.7M | -$19.4M |
| Diluted EPS | -$11.93 | -$68.01 | -$3.60 | -$12.71 | — |
| Operating cash flow | -$6.5M | -$6.9M | -$6.8M | -$11.2M | -$11.9M |
| Free cash flow | — | — | — | — | -$12.0M |
| Total assets | $6.7M | $5.0M | $4.7M | $5.7M | $7.5M |
| Total liabilities | $1.4M | $975,858 | $653,076 | $2.5M | $4.0M |
| Stockholders' equity | $5.3M | $4.1M | $4.1M | $3.3M | $3.5M |
| Cash and investments | $5.9M | $3.8M | $2.8M | $4.0M | $6.1M |
| Total debt | — | — | — | $207,375 | $256,960 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q/A | Amended quarterly report | Oct 21, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 16, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 18, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 16, 2026 | Sep 16, 2026 |
All 575 Adial Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.